

Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer

Information for the public

Published: 5 November 2025

www.nice.org.uk

Cemiplimab (Libtayo) with platinum-based chemotherapy is not normally available on the NHS for untreated non-small-cell lung cancer (NSCLC) in adults when the cancer:

- is locally advanced (has spread to nearby tissues) and chemotherapy with radiotherapy is not suitable, or
- is metastatic (has spread to other parts of the body), and
- has a protein called PD-L1 in 1% or more of the tumour cells, and
- has no genetic changes that affect the EGFR, ALK or ROS-1 genes.

Your healthcare professional should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

Information and support

The [NHS webpage on lung cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Roy Castle Lung Cancer Foundation](#), 0333 323 7200
- [Lung Cancer Nursing UK \(LCNUK\)](#), 01675 477607
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-7250-0